Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H26N4O5S |
Molecular Weight | 482.552 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=CC(C)=C1N(CC(=O)NC2=CC=C(C=C2)C3=NOC=N3)C(=O)C4CCS(=O)(=O)CC4
InChI
InChIKey=MNHNIVNAFBSLLX-UHFFFAOYSA-N
InChI=1S/C24H26N4O5S/c1-16-4-3-5-17(2)22(16)28(24(30)19-10-12-34(31,32)13-11-19)14-21(29)26-20-8-6-18(7-9-20)23-25-15-33-27-23/h3-9,15,19H,10-14H2,1-2H3,(H,26,29)
Amenamevir is an antiviral agent discovered by Astellas Pharma Inc. and is considered to exert anantiviral effect by inhibiting the activity of the helicase-primase complex, which is involved in DNA replication of herpes virus. It is a helicase-primase inhibitor against herpes simplex virus 1 (HSV-1), HSV-2, and varicella zoster virus. Amenamevir inhibited the in vitro replication of HSV-1 with a mean 50% effective concentration (EC(50)) of 14 ng/ml. Amenamevir was approved in Japan for the treatment of Herpes zoster.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: http://www.pmda.go.jp/files/000227731.pdf
Herpes zoster: The usual adult dosage is 400 mg of amenamevir administered orally once daily after a meal
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.pmda.go.jp/files/000227731.pdf
Curator's Comment: Amenamevir inhibits the replication of the HSV strains isolated in Japan and the United States as well as the laboratory-stocked strains. The mean EC50s of Amenamevir against HSV-1 and HSV-2 are 14 (range, 7.7 to 20) and 30 ng/mL (range, 15 to 58), respectively. https://www.ncbi.nlm.nih.gov/pubmed/23274658
Amenamevir inhibited the DNA-dependent ATPase activity of the HSV-1 helicase-primase complex within the concentration range from 0.0001 to 3 umol/L in a concentration-dependent manner, and the 50% inhibitory concentration (IC50) was 0.078 umol/L.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C281
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
11397521
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY | |||
|
9054
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY | |||
|
100000175542
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY | |||
|
C90782
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY | |||
|
Amenamevir
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY | |||
|
DTXSID101027753
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY | |||
|
94X46KW4AE
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY | |||
|
m12086
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY | |||
|
841301-32-4
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY | |||
|
DB11701
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY | |||
|
5266
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY |
ACTIVE MOIETY